MSB 1.08% 91.5¢ mesoblast limited

Robbo,Athersys covered by SCE on page 49 of 3/3/2011 report ( No...

  1. 384 Posts.
    lightbulb Created with Sketch. 5
    Robbo,

    Athersys covered by SCE on page 49 of 3/3/2011 report ( No 10 of listed competitors) and they did a small partnering deal with Pfizer in Dec 2009(pre MSB/CEPH).

    This was on the back of Pfizer launching there own regenerative research unit in November 2008.
    http://www.businesswire.com/news/home/20081114005161/en/Pfizer-Launches-Global-Regenerative-Medicine-Research-Unit

    Competion is good Robbo( albeit only small IMO and Msb yrs ahead)...and it keeps MSB management focused.

    By the way on 7/2/2011 Pfizer announced due to R & D cuts they were abandoning there regenerative medicine research in Cambridge.
    http://pubs.acs.org/cen/news/89/i06/8906notw1.html.

    Wouldnt know what this means but IMHO reading b/w the lines there is a lot more work to be done if Pfizer want to be a major player in the $bn dollar regenerative medicine industry.

    In my view, I see their alliance with Athersys as a positive for the Stem Cell Industry.

    Cheers.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
91.5¢
Change
-0.010(1.08%)
Mkt cap ! $1.044B
Open High Low Value Volume
94.0¢ 94.0¢ 91.5¢ $1.609M 1.737M

Buyers (Bids)

No. Vol. Price($)
12 131951 91.5¢
 

Sellers (Offers)

Price($) Vol. No.
92.5¢ 22000 1
View Market Depth
Last trade - 16.10pm 10/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.